Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The clinical results justify the hype
Obese patients whose records did show a CUD diagnosis prior to the study period were 38% less likely to have a recurrent CUD diagnosis during the study period if they received semaglutide compared to those not receiving the medication (HR: 0.62)
Start with whats on your plate
Sources: SURMOUNT-5 Clinical Trial (May 2025, The first head-to-head trial comparing the efficacy and safety of tirzepatide versus semaglutide for obesity management, detailing differences in total weight reduction
US$ 29.04
US$ 21.50
US$ 27.90
US$ 25.17
US$ 21.09
